ImageneBio, Inc. (IMA) - Net Assets
Based on the latest financial reports, ImageneBio, Inc. (IMA) has net assets worth $133.14 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($152.98 Million) and total liabilities ($19.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ImageneBio, Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $133.14 Million |
| % of Total Assets | 87.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | -35.95% |
| 10-Year Change | N/A |
| Growth Volatility | 19.44 |
ImageneBio, Inc. - Net Assets Trend (2018–2025)
This chart illustrates how ImageneBio, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of ImageneBio, Inc. for the complete picture of this company's asset base.
Annual Net Assets for ImageneBio, Inc. (2018–2025)
The table below shows the annual net assets of ImageneBio, Inc. from 2018 to 2025. For live valuation and market cap data, see market value of ImageneBio, Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $133.14 Million | +5.72% |
| 2024-12-31 | $125.93 Million | -25.82% |
| 2023-12-31 | $169.76 Million | +15.51% |
| 2022-12-31 | $146.97 Million | -29.30% |
| 2021-12-31 | $207.88 Million | +305.72% |
| 2020-12-31 | $-101.05 Million | -64.40% |
| 2019-12-31 | $-61.46 Million | -34.08% |
| 2018-12-31 | $-45.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ImageneBio, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17978700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.01% |
| Other Comprehensive Income | $87.00K | 0.07% |
| Other Components | $363.09 Million | 272.72% |
| Total Equity | $133.14 Million | 100.00% |
ImageneBio, Inc. Competitors by Market Cap
The table below lists competitors of ImageneBio, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Binh Duong Trade and Development JSC
VN:TDC
|
$53.17 Million |
|
A.J. Plast Public Company Limited
BK:AJ
|
$53.17 Million |
|
Tinka Resources Limited
V:TK
|
$53.18 Million |
|
Sarveshwar Foods Limited
NSE:SARVESHWAR
|
$53.19 Million |
|
LEIFRAS Co., Ltd. American Depositary Shares
NASDAQ:LFS
|
$53.11 Million |
|
Hyundai Engineering & Construction Co Ltd
KO:000725
|
$53.11 Million |
|
Widodo Makmur Unggas Tbk PT
JK:WMUU
|
$53.08 Million |
|
Yesil Gayrimenkul Yatirim Ortakligi AS
IS:YGYO
|
$53.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ImageneBio, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 125,934,000 to 133,139,000, a change of 7,205,000 (5.7%).
- Net loss of 45,349,000 reduced equity.
- New share issuances of 71,130,000 increased equity.
- Other comprehensive income increased equity by 19,000.
- Other factors decreased equity by 18,595,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-45.35 Million | -34.06% |
| Share Issuances | $71.13 Million | +53.43% |
| Other Comprehensive Income | $19.00K | +0.01% |
| Other Changes | $-18.59 Million | -13.97% |
| Total Change | $- | 5.72% |
Book Value vs Market Value Analysis
This analysis compares ImageneBio, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.21x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-1.28 | $5.66 | x |
| 2019-12-31 | $-1.71 | $5.66 | x |
| 2020-12-31 | $-7.22 | $5.66 | x |
| 2021-12-31 | $5.78 | $5.66 | x |
| 2022-12-31 | $4.06 | $5.66 | x |
| 2023-12-31 | $4.07 | $5.66 | x |
| 2024-12-31 | $2.61 | $5.66 | x |
| 2025-12-31 | $27.33 | $5.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ImageneBio, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5668.62%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.15x
- Recent ROE (-34.06%) is below the historical average (-20.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -4127.78% | 0.05x | 0.00x | $-36.28 Million |
| 2019 | 0.00% | -122.28% | 0.16x | 0.00x | $-10.67 Million |
| 2020 | 0.00% | -481.36% | 0.05x | 0.00x | $-34.15 Million |
| 2021 | -16.41% | -110.10% | 0.13x | 1.19x | $-54.90 Million |
| 2022 | -46.79% | -440.29% | 0.09x | 1.17x | $-83.46 Million |
| 2023 | -40.16% | -744.17% | 0.05x | 1.13x | $-85.14 Million |
| 2024 | -29.04% | -1044.80% | 0.02x | 1.12x | $-49.16 Million |
| 2025 | -34.06% | -5668.63% | 0.01x | 1.15x | $-58.66 Million |
Industry Comparison
This section compares ImageneBio, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ImageneBio, Inc. (IMA) | $133.14 Million | 0.00% | 0.15x | $53.13 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more